# About Retatrutide Legit > About Retatrutide Legit — an independent editorial project publishing summaries of the peer-reviewed research on retatrutide. Not a clinic, not a vendor, not a prescription. ## What this site is Retatrutide Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide. Every quantitative claim on this site is cited to a primary source — a published trial, a structural pharmacology paper, or a trial registration on ClinicalTrials.gov. The citations are in the text and they are on the references page. The site exists because the retatrutide information environment is noisy: approved-drug claims are circulating about a compound that is not approved, vendor promotions are dressed up as research summaries, and the actual trial record is scattered across NEJM, Lancet, Nature Medicine, and ClinicalTrials.gov. The editorial function here is to read those sources directly and report what they say. ## What this site is not We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We have no pricing information, no vendor relationships, and no order forms. Our work is editorial commentary on publicly available science. The word "legit" in the domain is an editorial position — a signal that this is a site that reads the actual trial record rather than parroting gray-market promotional copy. It is not a claim that any particular use or source of retatrutide is legitimate. Retatrutide is an investigational compound. The clinical trial is the legitimate context. Everything else is gray market. ## The "Legit" framing: a note on domain names This site's domain name signals an editorial intent: due diligence, source verification, noise-filtering. It does not imply that this site provides medical legitimacy or that it validates any source, vendor, or use case for retatrutide. Other retatrutide research sites in this portfolio have names referencing clinics, doctors, or pharmacies. These are SEO domain names. None of these sites is operated by a clinic, employs doctors, or fills prescriptions. They are all independent editorial publishers summarizing the same compound through different editorial lenses. This site's lens is regulatory due diligence — sorting what the trials established from what the gray-market claims. ## Editorial standard Every page on this site distinguishes between: (1) cited clinical findings from peer-reviewed trials — these are stated as research findings with citation numbers; (2) community-reported anecdotal experiences — these are labeled explicitly as "anecdotal, not clinical evidence" in the effects section; and (3) open questions and ongoing trials — these are stated as open and noted as pending. No AI-generated content is stated as fact without a primary source. No claim is made without a citation the reader can verify. If the trial has not measured something, this site does not state it as a finding. --- The trial record on retatrutide, read straight — investigational findings logged to source, gray-market noise filtered out, nothing here approved, prescribed, or sold.